Vanessa Glennon

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: July 13, 2026

Perioperative use of disease-modifying anti-rheumatic drugs (DMARDs) in people with inflammatory arthritis.

Perioperative use of disease-modifying anti-rheumatic drugs (DMARDs) in people with inflammatory arthritis.

Journal: The Cochrane database of systematic reviews

Published: May 20, 2026

Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity.

Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity.

Journal: The Cochrane database of systematic reviews

Published: September 30, 2025

Get Involved Reach Top Health (GIRTH): A community-based, peer-led group lifestyle modification program for men - A quasi-randomised trial.

Get Involved Reach Top Health (GIRTH): A community-based, peer-led group lifestyle modification program for men - A quasi-randomised trial.

Journal: Obesity research & clinical practice

Published: April 03, 2025

Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.

Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.

Journal: The Cochrane database of systematic reviews

Published: December 16, 2024

Living recommendations do not "flip-flop": examining the probability of directional changes to recommendations in living guidelines.

Living recommendations do not "flip-flop": examining the probability of directional changes to recommendations in living guidelines.

Journal: Journal of clinical epidemiology

Published: October 10, 2024

Crowd-sourcing and automation facilitated the identification and classification of randomized controlled trials in a living review.

Crowd-sourcing and automation facilitated the identification and classification of randomized controlled trials in a living review.

Journal: Journal of clinical epidemiology

Published: August 21, 2023

Prioritization of clinical questions for the Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis.

Prioritization of clinical questions for the Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis.

Journal: International journal of rheumatic diseases

Published: June 13, 2023

Australian recommendations on perioperative use of disease-modifying anti-rheumatic drugs in people with inflammatory arthritis undergoing elective surgery.

Australian recommendations on perioperative use of disease-modifying anti-rheumatic drugs in people with inflammatory arthritis undergoing elective surgery.

Journal: Internal medicine journal

Published: October 23, 2022

Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.

Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.

Journal: Internal medicine journal

Published: February 25, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026